BG61677B1 - Лекарствена форма за орално приложение за лечение назаболявания, свързани с липсата на допамин - Google Patents

Лекарствена форма за орално приложение за лечение назаболявания, свързани с липсата на допамин Download PDF

Info

Publication number
BG61677B1
BG61677B1 BG97894A BG9789493A BG61677B1 BG 61677 B1 BG61677 B1 BG 61677B1 BG 97894 A BG97894 A BG 97894A BG 9789493 A BG9789493 A BG 9789493A BG 61677 B1 BG61677 B1 BG 61677B1
Authority
BG
Bulgaria
Prior art keywords
saponified polyvinyl
polyvinyl alcohol
dosage form
surface area
total surface
Prior art date
Application number
BG97894A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG97894A (bg
Inventor
Udo Wenzel
Guenther Weber
Juergen Metzner
Alfred Daerr
Sabine Freitag
Frank-Ulrich Floether
Frank-Michael Albert
Margit Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of BG97894A publication Critical patent/BG97894A/bg
Publication of BG61677B1 publication Critical patent/BG61677B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG97894A 1991-01-23 1993-06-22 Лекарствена форма за орално приложение за лечение назаболявания, свързани с липсата на допамин BG61677B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
PCT/DE1992/000043 WO1992012710A1 (de) 1991-01-23 1992-01-23 Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustände

Publications (2)

Publication Number Publication Date
BG97894A BG97894A (bg) 1994-04-29
BG61677B1 true BG61677B1 (bg) 1998-03-31

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
BG97894A BG61677B1 (bg) 1991-01-23 1993-06-22 Лекарствена форма за орално приложение за лечение назаболявания, свързани с липсата на допамин

Country Status (22)

Country Link
US (1) US5532274A (sv)
EP (1) EP0568577B1 (sv)
JP (1) JP3382940B2 (sv)
AT (1) ATE147264T1 (sv)
AU (1) AU658171B2 (sv)
BG (1) BG61677B1 (sv)
CA (1) CA2101164C (sv)
CZ (1) CZ280847B6 (sv)
DE (2) DE4101873C2 (sv)
DK (1) DK0568577T3 (sv)
EE (1) EE03016B1 (sv)
ES (1) ES2098496T3 (sv)
FI (1) FI101040B (sv)
GR (1) GR3022993T3 (sv)
LT (1) LT3659B (sv)
LV (1) LV11103B (sv)
NO (1) NO304638B1 (sv)
RO (1) RO114737B1 (sv)
RU (1) RU2114619C1 (sv)
SK (1) SK369292A3 (sv)
UA (1) UA27848C2 (sv)
WO (1) WO1992012710A1 (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (sv) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaceutisk komposition
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
DE60237294D1 (de) * 2001-09-28 2010-09-23 Mcneil Ppc Inc Pharmazeutische zusammensetzung auf fondantbasis
KR20050083750A (ko) * 2002-10-11 2005-08-26 디포메드 디벨롭먼트 리미티드 위-체류성 레보도파 전달 형태
WO2005023185A2 (en) 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
EP1863455A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of parkinson's disease
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
KR101752080B1 (ko) 2007-12-28 2017-06-28 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
JP6694564B1 (ja) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 結合剤
WO2020100933A1 (ja) * 2018-11-13 2020-05-22 日本酢ビ・ポバール株式会社 結合剤
EP3881838A4 (en) * 2018-11-13 2022-08-17 Japan Vam & Poval Co., Ltd. ADHESIVE
EP4134103A4 (en) * 2020-04-10 2024-04-24 Japan Vam & Poval Co., Ltd. BINDER
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
ES2052681T5 (es) * 1987-12-31 1997-12-01 Asta Medica Ag Combinacion sinergica de inhibidores de descarboxilasa y granulos de l-dopa.
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets

Also Published As

Publication number Publication date
WO1992012710A1 (de) 1992-08-06
AU1186892A (en) 1992-08-27
FI933304A (fi) 1993-07-22
AU658171B2 (en) 1995-04-06
CZ369292A3 (en) 1993-09-15
EP0568577A1 (de) 1993-11-10
CA2101164C (fr) 2001-04-24
ES2098496T3 (es) 1997-05-01
SK278736B6 (sk) 1998-02-04
UA27848C2 (uk) 2000-10-16
SK369292A3 (en) 1998-02-04
NO932522L (no) 1993-07-09
LV11103B (en) 1996-06-20
JP3382940B2 (ja) 2003-03-04
DE59207852D1 (de) 1997-02-20
FI933304A0 (fi) 1993-07-22
DK0568577T3 (da) 1997-06-30
US5532274A (en) 1996-07-02
NO304638B1 (no) 1999-01-25
ATE147264T1 (de) 1997-01-15
LV11103A (lv) 1996-04-20
EP0568577B1 (de) 1997-01-08
BG97894A (bg) 1994-04-29
RO114737B1 (ro) 1999-07-30
EE03016B1 (et) 1997-08-15
LT3659B (en) 1996-01-25
JPH06504543A (ja) 1994-05-26
RU2114619C1 (ru) 1998-07-10
CZ280847B6 (cs) 1996-04-17
FI101040B (sv) 1998-04-15
LTIP555A (en) 1994-11-25
GR3022993T3 (en) 1997-07-30
CA2101164A1 (fr) 1992-07-24
DE4101873A1 (de) 1992-07-30
DE4101873C2 (de) 1993-12-09
NO932522D0 (no) 1993-07-09

Similar Documents

Publication Publication Date Title
BG61677B1 (bg) Лекарствена форма за орално приложение за лечение назаболявания, свързани с липсата на допамин
KR960005706B1 (ko) 경구용 서방성 아세트아미노펜 제형 및 이의 제조방법
US5211958A (en) Pharmaceutical composition and process for its preparation
CN110833544A (zh) 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
RU2001110355A (ru) Независящие от влияния пищи фармацевтические дозированные препаративные формы пролонгированного действия, содержащие множество единиц, и способ их получения
US5624960A (en) Orally administrable drugs for the treatment of central dopamine deficiency conditions
HU228149B1 (en) Film coated tablet of paracetamol and domperidone
NO173081B (no) Fremgangsmaate for fremstilling av et retard-preparat av ibuprofen
JP3625825B2 (ja) β−フェニルプロピオフェノン誘導体の遅延マイクロ錠剤
WO2007058397A1 (en) A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same
GR1009644B (el) Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
EP3020416A1 (en) Ultrafast-disintegrating tablet and method for manufacturing same
MXPA04009906A (es) Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda.
Yasmeen et al. Comparative study of different formulations of atenolol
CA1334933C (en) Pharmaceutical composition and process for its preparation
KR20180098282A (ko) 압축 성형 제제
KR20170056574A (ko) 알펠리십을 포함하는 제약 조성물
JP2016060731A (ja) 経口組成物
KR20200015758A (ko) 제약 조성물
Kolli et al. Formulation and evaluation of matrix tablet of ramipril
DD301037A5 (de) Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
GR1010510B (el) Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης
Chavan et al. FORMULATION AND EVALUATION OF METFORMIN AND GLIMEPIRIDE BILAYERED TABLET
JP2023157789A (ja) グアンファシン含有徐放性製剤
RU2199313C1 (ru) Препарат для лечения и профилактики дисбактериоза и повышения неспецифической резистентности организма человека